A Study of SNDX-5613 in Relapsed/Refractory Acute Leukemias With a Mixed Lineage Leukemia (MLL)/KMT2A Gene Rearrangement or NPM1 Mutation1
Revumenib/SNDX-5613 is an investigational, novel, orally available Menin-MLL1 inhibitor.2 The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 mutation.3,4
Prevalence5
- MLL rearrangements are found in 5% to 10% of adult AML and B-ALL cases and >70% of infant leukemias
- NPM1 mutations are found in about 25% to 30% of all adult AML
AUGMENT-101/NCT04065399: A Phase 1/2, Open-Label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/ refractory acute leukemias harboring a mixed lineage leukemia (MLL)/KMT2A gene rearrangement or Nucleophosmin 1 (NPM1) mutation.1
This trial is actively recruiting